AT1拮抗剂氯沙坦降压治疗对患者血浆一氧化氮的影响

Effects of antihypertensive treatment with AT1 receptor antagonist losartan on plasma nitric oxide levels in hypertensives

目的 探讨血管紧张素Ⅱ的Ⅰ型受体 (AT1)拮抗剂氯沙坦对高血压患者除降压作用外对血浆一氧化氮(N0 )的影响。方法 应用硝酸还原酶法对 10 0例高血压患者 (分为氯沙坦治疗组及洛汀新治疗组各 50例 )治疗前后及血压正常之对照组 3 0例的血浆N0浓度进行测定。结果 高血压组 (两组 )患者治疗前血浆N0浓度明显低于正常对照组 (P <0。 0 5) ,以氯沙坦和血管紧张素转换酶抑制剂 (A CEI)洛汀新有效降压后血浆N0浓度均有明显提高 ,差异有统计学意义 (P <0 0 5)。治疗前后两治疗组间的血浆N0浓度无差异。结论 氯沙坦与洛汀新除有良好的降压作用外均可升高高血压患者的血浆NO水平 。

Objectives To investigate the influence of AT1 receptor antagonist losartan on plasma nitric oxide (N0) levels in patients with hypertension besides its antihypertensive effect. Methods The plasma N0 levels in controls with 30 cases and in 100 hypertension patients (losartan group and lotensin group each with 50 patients) before and after antihypertensive treatment were tested using the method of nitric acid reductase. Results The N0 levels in patients with hypertension were significantly lower than those in control before treatment ( P <0 05) and were significantly increased after treatment with losartan and ACE inhibitor lotensin, both the difference were statistically significant ( P <0 05). Conclusions Both losartan and lotensin can increase the plasma N0 levels in patients with hypertension besides their antihypertensive effect and they show the same effect on elevation of plasma N0 levels.